Nancy Ratner PhD

Nancy Ratner PhD
ProfessorCollege of
Room R-2325, MLC 7013 3333 Burnet Ave Cincinnati OH 452293039
Phone:513-636-9469Fax: 513-636-3549
  • Molecular Biology and Cancer Genetics

General Research Interest

Central- Brain and peripheral nerve tumors and Neurofibromatosis

Research Description

The long term interest of the Ratner laboratory is to define the interactions between glial cells and axons during nervous system development and how those interactions go awry in disease, with the goal of providing novel therapies to patients with nervous system diseases. Neurofibromatosis type 1 (NF1) is an inherited autosomal dominant disorder (1:3500 humans) that involves the formation of many nerve-associated tumors and other non-tumor related problems. Neurofibromatosis type 2 (NF2) involves the development of Schwannomas, benign tumors composed of Schwann cells (peripheral glial cells). Elucidating the mechanisms by which the nerve-associated tumors arise in both diseases can not only lead to the development of therapy for NF1 and NF2 patients, but can also useful in providing information about non-inherited nervous system cancers.

Current Publications

  • Waclaw RRThe protein tyrosine phosphatase shp2 is required for the generation of oligodendrocyte progenitor cells and myelination in the mouse telencephalon.J Neurosci 34 3767-78 3/5/2014
  • Morrison HCTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.Am J Med Genet A 164A 563-78 3/1/2014
  • Ratner NMAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.Oncogene 2/10/2014
  • Largaespada DACo-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.Oncotarget 1/20/2014
  • Guo L, Moon C, Zheng Y, Ratner NCdc42 regulates Schwann cell radial sorting and myelin sheath folding through NF2/merlin-dependent and independent signaling.Glia 61 1906-21 11/1/2013
  • Mayes DA, Rizvi TA, Titus-Mitchell H, Oberst R, Ciraolo GM, Vorhees CV, Robinson AP, Miller SD, Cancelas JA, Stemmer-Rachamimov AO, Ratner NNf1 loss and Ras hyperactivation in oligodendrocytes induce NOS-driven defects in myelin and vasculature.Cell Rep 4(6) 1197-212 9/26/2013
  • Rahrmann EP, Watson AL, Keng VW, Choi K, Moriarity BS, Beckmann DA, Wolf NK, Sarver A, Collins MH, Moertel CL, Wallace MR, Gel B, Serra E, Ratner N, Largaespada DAForward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.Nat Genet 45(7) 756-66 7/1/2013
  • Watson AL, Rahrmann EP, Moriarity BS, Choi K, Conboy CB, Greeley AD, Halfond AL, Anderson LK, Wahl BR, Keng VW, Rizzardi AE, Forster CL, Collins MH, Sarver A, Wallace MR, Schmechel SC, Ratner N, Largaespada DACanonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.Cancer Discov 3(6) 674-89 6/1/2013
  • Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, Giovannini MUpdate from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.Am J Med Genet A 161A(3) 405-16 3/1/2013
  • Wu J, Patmore DM, Jousma E, Eaves DW, Breving K, Patel AV, Schwartz EB, Fuchs JR, Cripe TP, Stemmer-Rachamimov AO, Ratner NEGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors.Oncogene in press 1/14/2013
  • Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Dudley AH, Niwa-Kawakita M, Page GP, Giovannini M, Aronow B, Cripe TP, Ratner NMEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.J Clin Invest 123(1) 340-7 1/2/2013
  • Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, Cancelas JA, Dombi E, Kim MO, West BL, Bollag G, Ratner NNeurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.Acta Neuropathol 125(1) 159-68 1/1/2013
  • Patmore DM, Welch S, Fulkerson PC, Wu J, Choi K, Eaves D, Kordich JJ, Collins MH, Cripe TP, Ratner NIn vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGAP protein NF1.Cancer Res 72(20) 5317-27 10/15/2012
  • Gutmann DH, Parada LF, Silva AJ, Ratner NNeurofibromatosis type 1: modeling CNS dysfunction.J Neurosci 32(41) 14087-93 10/10/2012
  • Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow B, Perentesis J, Serra E, Cripe T, Miller SC, Ratner NRas-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.Clin Cancer Res 18(18) 5020-30 9/15/2012
  • Acosta MT, Bearden CE, Castellanos XF, Cutting L, Elgersma Y, Gioia G, Gutmann DH, Lee YS, Legius E, Muenke M, North K, Parada LF, Ratner N, Hunter-Schaedle K, Silva AJThe Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research.Am J Med Genet A 158A(9) 2225-32 9/1/2012
  • Keng VW, Rahrmann EP, Watson AL, Tschida BR, Moertel CL, Jessen WJ, Rizvi TA, Collins MH, Ratner N, Largaespada DAPTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors.Cancer Res 72(13) 3405-13 7/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: